Horizon Discovery join AIM
Thursday 27th March 2014
London Stock Exchange is delighted to welcome Horizon Discovery Group plc (“Horizon”) to the AIM market today. The revenue generating life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines, has raised £68.6 million, giving the Company a market capitalization of £120.5 million. Horizon will trade under the ticker “HZD” from March 27th, 2014.
Horizon’s aim is to become a global market-leader in the provision of Life Science research tools that enable the understanding of the genetic basis of disease and the development of personalised medicines that deliver better outcomes for patients.
Proceeds from the IPO will be used to enhance the global profile of Horizon Discovery, expand its sales and distribution channels, boost its product lines and increase its geographic footprint and opportunities in leveraged R&D.
Commenting on its successful admission to AIM, Dr. Darrin Disley, CEO of Horizon Discovery Group plc, said:
“We are delighted to be joining AIM, and we wish to thank our investors for their continued and fresh support. The enthusiasm and substantial interest in the placing demonstrates the value of our technology and our powerful business model. The listing of our shares is a significant milestone in Horizon’s development and we expect to unlock and deliver significant value to all shareholders moving forward.”
Panmure Gordon has acted as nominated adviser and broker to the Horizon during the IPO.